Publications by authors named "Patrick Dorr"

Claim this Profile
B
Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study.
Moti N Ramgopal, Jacob P Lalezari, Ana Gabriela Pires Dos Santos, Preethi Krishnan, Tanaya R Vaidya, Patrick Dorr

Nat Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequences.
Justin E Ideozu, Mengzhen Liu, Bridget M Riley-Gillis, Sri R Paladugu, Fedik Rahimov, Patrick Dorr

Genome Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
Daniel Clark Files, Frank Tacke, Alexandra O'Sullivan, Patrick Dorr, William G Ferguson

PLoS Pathog· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers for the clinical development of antiviral therapies.
Teresa I Ng, Patrick K Dorr, Preethi Krishnan, Daniel E Cohen, Susan Rhee

Cytometry B Clin Cytom· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
Peter Ferenci, Stefan Bourgeois, Peter Buggisch, Suzanne Norris, Manuela Curescu, Patrick Dorr

J Viral Hepat· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.
Maria Espirito-Santo, Quirina Santos-Costa, Marta Calado, Patrick Dorr, J Miguel Azevedo-Pereira

AIDS Res Hum Retroviruses· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).
Paul A Stupple, David V Batchelor, Martin Corless, Patrick K Dorr, David Ellis

J Med Chem· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR5 pharmacology methodologies and associated applications.
Roy Mansfield, Sarah Able, Paul Griffin, Becky Irvine, Ian James, Patrick Dorr

Methods Enzymol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR5 inhibitors in HIV-1 therapy.
Patrick Dorr, Manos Perros

Expert Opin Drug Discov· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Mike Westby, Caroline Smith-Burchnell, Julie Mori, Marilyn Lewis, Michael Mosley, Patrick Dorr

J Virol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
Samantha Willey, Paul J Peters, W Matthew Sullivan, Patrick Dorr, Manos Perros

Antiviral Res· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Patrick Dorr, Mike Westby, Susan Dobbs, Paul Griffin, Becky Irvine

Antimicrob Agents Chemother· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel small-molecule inhibitors of RNA polymerase III.
Liping Wu, Jing Pan, Vala Thoroddsen, Deborah R Wysong, Ronald K Blackman, Patrick K Dorr

Eukaryot Cell· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis